Melancholic features related to rimonabant.
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFOP |
Texto Completo: | http://www.repositorio.ufop.br/handle/123456789/3767 https://doi.org/10.1016/j.genhosppsych.2008.12.009 |
Resumo: | Introduction: Obesity is currently considered a global epidemic and its prevention and treatment is a major public health concern, demanding treatment which may combine a sociocultural approach, lifestyle modification, nutritional, pharmacological or surgical strategies. Rimonabant, an endocannabinoid antagonist, has been proposed as an agent for an average weight loss of 4 kg. However, the development of anxiety and depressive symptoms can be major side effects. Case Report: A 27-year-old businessman, after using rimonabant (20 mg/day) for 1 month for weight loss, developed a major depressive episode with melancholic features, which remitted after the interruption of rimonabant. Discussion: To our knowledge, a major depressive episode with melancholic or atypical features specifier has not been described since the initiation of rimonabant pharmacological trials. The Hospital Anxiety and Depression Scale, used in the rimonabant trials, assesses several key points of depressive patients. However, it neglects the somatic symptoms that correspond to the additional criterion for both of the mentioned features as well as suicidal ideation. The severity of an episode could also be underestimated depending on the assessment tool or on the clinical interview. Conclusion: There may be an underestimation of depressive melancholic and atypical side effects related to Rimonabant use, due to the lack of consistent assessment with the appropriate screening tools. Pharmacological strategies should be adjunctive for obesity treatment when there is a failure in the lifestyle and nutritional modification strategies. Moreover, deeper global sociocultural changes should be made in the treatment and control of the global obesity epidemic. |
id |
UFOP_c5a6ae819efec6a9d84fb2d2f95df6ff |
---|---|
oai_identifier_str |
oai:repositorio.ufop.br:123456789/3767 |
network_acronym_str |
UFOP |
network_name_str |
Repositório Institucional da UFOP |
repository_id_str |
3233 |
spelling |
Melancholic features related to rimonabant.RimonabantDepressionMelancholic featuresObesityIntroduction: Obesity is currently considered a global epidemic and its prevention and treatment is a major public health concern, demanding treatment which may combine a sociocultural approach, lifestyle modification, nutritional, pharmacological or surgical strategies. Rimonabant, an endocannabinoid antagonist, has been proposed as an agent for an average weight loss of 4 kg. However, the development of anxiety and depressive symptoms can be major side effects. Case Report: A 27-year-old businessman, after using rimonabant (20 mg/day) for 1 month for weight loss, developed a major depressive episode with melancholic features, which remitted after the interruption of rimonabant. Discussion: To our knowledge, a major depressive episode with melancholic or atypical features specifier has not been described since the initiation of rimonabant pharmacological trials. The Hospital Anxiety and Depression Scale, used in the rimonabant trials, assesses several key points of depressive patients. However, it neglects the somatic symptoms that correspond to the additional criterion for both of the mentioned features as well as suicidal ideation. The severity of an episode could also be underestimated depending on the assessment tool or on the clinical interview. Conclusion: There may be an underestimation of depressive melancholic and atypical side effects related to Rimonabant use, due to the lack of consistent assessment with the appropriate screening tools. Pharmacological strategies should be adjunctive for obesity treatment when there is a failure in the lifestyle and nutritional modification strategies. Moreover, deeper global sociocultural changes should be made in the treatment and control of the global obesity epidemic.2014-11-11T17:57:48Z2014-11-11T17:57:48Z2009info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfVIANA, B. M; PRAIS, H. A. C; DAKER, M. V. et al. Melancholic features related to rimonabant. General Hospital Psychiatry, v. 31, p. 583-585, 2009. Disponível em: <http://www.sciencedirect.com/science/article/pii/S0163834309000061>. Acesso em: 03 set. 2014.0163-8343http://www.repositorio.ufop.br/handle/123456789/3767https://doi.org/10.1016/j.genhosppsych.2008.12.009O periódico General Hospital Psychiatry concede permissão para depósito deste artigo no Repositório Institucional da UFOP. Número da licença: 3462660863709.info:eu-repo/semantics/openAccessViana, Bernardo de MattosCano Prais, Hugo AlejandroDaker, Maurício Viottiengreponame:Repositório Institucional da UFOPinstname:Universidade Federal de Ouro Preto (UFOP)instacron:UFOP2019-05-07T13:20:42Zoai:repositorio.ufop.br:123456789/3767Repositório InstitucionalPUBhttp://www.repositorio.ufop.br/oai/requestrepositorio@ufop.edu.bropendoar:32332019-05-07T13:20:42Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP)false |
dc.title.none.fl_str_mv |
Melancholic features related to rimonabant. |
title |
Melancholic features related to rimonabant. |
spellingShingle |
Melancholic features related to rimonabant. Viana, Bernardo de Mattos Rimonabant Depression Melancholic features Obesity |
title_short |
Melancholic features related to rimonabant. |
title_full |
Melancholic features related to rimonabant. |
title_fullStr |
Melancholic features related to rimonabant. |
title_full_unstemmed |
Melancholic features related to rimonabant. |
title_sort |
Melancholic features related to rimonabant. |
author |
Viana, Bernardo de Mattos |
author_facet |
Viana, Bernardo de Mattos Cano Prais, Hugo Alejandro Daker, Maurício Viotti |
author_role |
author |
author2 |
Cano Prais, Hugo Alejandro Daker, Maurício Viotti |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Viana, Bernardo de Mattos Cano Prais, Hugo Alejandro Daker, Maurício Viotti |
dc.subject.por.fl_str_mv |
Rimonabant Depression Melancholic features Obesity |
topic |
Rimonabant Depression Melancholic features Obesity |
description |
Introduction: Obesity is currently considered a global epidemic and its prevention and treatment is a major public health concern, demanding treatment which may combine a sociocultural approach, lifestyle modification, nutritional, pharmacological or surgical strategies. Rimonabant, an endocannabinoid antagonist, has been proposed as an agent for an average weight loss of 4 kg. However, the development of anxiety and depressive symptoms can be major side effects. Case Report: A 27-year-old businessman, after using rimonabant (20 mg/day) for 1 month for weight loss, developed a major depressive episode with melancholic features, which remitted after the interruption of rimonabant. Discussion: To our knowledge, a major depressive episode with melancholic or atypical features specifier has not been described since the initiation of rimonabant pharmacological trials. The Hospital Anxiety and Depression Scale, used in the rimonabant trials, assesses several key points of depressive patients. However, it neglects the somatic symptoms that correspond to the additional criterion for both of the mentioned features as well as suicidal ideation. The severity of an episode could also be underestimated depending on the assessment tool or on the clinical interview. Conclusion: There may be an underestimation of depressive melancholic and atypical side effects related to Rimonabant use, due to the lack of consistent assessment with the appropriate screening tools. Pharmacological strategies should be adjunctive for obesity treatment when there is a failure in the lifestyle and nutritional modification strategies. Moreover, deeper global sociocultural changes should be made in the treatment and control of the global obesity epidemic. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009 2014-11-11T17:57:48Z 2014-11-11T17:57:48Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
VIANA, B. M; PRAIS, H. A. C; DAKER, M. V. et al. Melancholic features related to rimonabant. General Hospital Psychiatry, v. 31, p. 583-585, 2009. Disponível em: <http://www.sciencedirect.com/science/article/pii/S0163834309000061>. Acesso em: 03 set. 2014. 0163-8343 http://www.repositorio.ufop.br/handle/123456789/3767 https://doi.org/10.1016/j.genhosppsych.2008.12.009 |
identifier_str_mv |
VIANA, B. M; PRAIS, H. A. C; DAKER, M. V. et al. Melancholic features related to rimonabant. General Hospital Psychiatry, v. 31, p. 583-585, 2009. Disponível em: <http://www.sciencedirect.com/science/article/pii/S0163834309000061>. Acesso em: 03 set. 2014. 0163-8343 |
url |
http://www.repositorio.ufop.br/handle/123456789/3767 https://doi.org/10.1016/j.genhosppsych.2008.12.009 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFOP instname:Universidade Federal de Ouro Preto (UFOP) instacron:UFOP |
instname_str |
Universidade Federal de Ouro Preto (UFOP) |
instacron_str |
UFOP |
institution |
UFOP |
reponame_str |
Repositório Institucional da UFOP |
collection |
Repositório Institucional da UFOP |
repository.name.fl_str_mv |
Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP) |
repository.mail.fl_str_mv |
repositorio@ufop.edu.br |
_version_ |
1813002831077048320 |